HK$12.43 close 28 Jan 2026: 2228.HK XtalPi Holdings Ltd (HKSE) under earnings focus
The market closed with XtalPi Holdings Ltd (2228.HK) at HK$12.43 on 28 Jan 2026, down 1.58% on the day as investors weigh AI drug-discovery progress against near-term earnings clarity. This 2228.HK stock update reviews price action, key ratios and technical signals that matter to Hong Kong investors. We focus on PE, cash runway, volume and short-term catalysts for the healthcare AI name listed on the HKSE.
2228.HK stock snapshot and intraday moves
XtalPi (2228.HK) closed at HK$12.43, down HK$0.20 from the prior close of HK$12.63, with a daily range HK$12.00–HK$12.68 and volume 89,200,345.00 shares. The stock trades on the HKSE and currently sits well above its 50-day average HK$10.61 and 200-day average HK$8.58, reflecting strong YTD momentum of 25.83% and 1-year gains of 153.94%.
2228.HK stock: business model and AI positioning
XtalPi Holdings Ltd offers AI-driven drug discovery and intelligent automation across China, the US, Europe, South Korea and Japan, targeting small molecules, antibodies, peptides and PROTACs. The company’s AI-first strategy positions it inside the healthcare technology segment where R&D intensity is high and sector peers show elevated price-to-sales multiples.
2228.HK stock valuation and financials
On reported figures XtalPi shows EPS HK$1.04 and a market PE of 12.09, with market cap HK$54,093,383,036.00 and shares outstanding 4,303,371,761.00. Key ratios show a high price-to-sales of 70.79 and PB of 6.03, while the current ratio is 9.69, indicating strong liquidity but stretched valuation versus healthcare sector averages.
2228.HK stock technicals and trading signals
Technicals show overbought momentum with RSI 76.82 and Stochastic %K 95.96, while ADX 30.64 points to a strong trend. Bollinger upper band sits near HK$11.80, and average volume remains elevated versus longer-term averages, suggesting institutional interest. Traders should watch support near HK$11.00 and resistance around the year high HK$15.12.
Meyka AI rates 2228.HK with a score out of 100 and model forecasts
Meyka AI rates 2228.HK with a score of 58.92 out of 100 — Grade C+ | Suggestion: HOLD. This grade factors S&P 500 and sector comparisons, financial growth, key metrics and analyst signals. Meyka AI’s forecast model projects a monthly target HK$16.04 (+29.06% vs HK$12.43), a quarterly target HK$11.67 (-6.11%) and a 12‑month target HK$10.46 (-15.85%). Forecasts are model-based projections and not guarantees.
2228.HK stock risks, catalysts and sector context
Key risks include slower-than-expected deal flow, clinical validation delays and valuation compression after rapid gains; sector peers show average PS near 59.70, making XtalPi’s PS of 70.79 a point of sensitivity. Catalysts: upcoming earnings announcement on 2026-03-27, new AI partnerships, and milestone payments from drug collaborations could support upside. See company details at XtalPi website and our Meyka stock page for updates.
Final Thoughts
At HK$12.43 on 28 Jan 2026, 2228.HK stock reflects a tension between strong investor interest in AI-enabled drug discovery and stretched valuation metrics. The stock trades above short- and medium-term moving averages, with liquidity ample (volume 89,200,345.00). Financials show EPS HK$1.04 and PE 12.09, but price-to-sales 70.79 and negative TTM cash-flow ratios highlight earnings conversion risk. Meyka AI’s forecast model projects a near-term monthly level of HK$16.04 (+29.06%) and a 12-month level of HK$10.46 (-15.85%), underscoring a wide scenario range. Our view frames XtalPi as a technology-heavy healthcare name where event risk around the 2026-03-27 earnings release and clinical milestones will likely drive next moves. Investors should weigh the C+ (58.92/100) Meyka grade, monitor upcoming revenue or partnership updates, and set risk limits given volatility. For ongoing live coverage and data-driven alerts, refer to Meyka AI’s platform and the company site for formal releases.
FAQs
What drove 2228.HK stock today
2228.HK stock fell to HK$12.43 on 28 Jan 2026, down 1.58%, as traders digested valuation vs growth and awaited the 2026-03-27 earnings announcement and partnership updates.
What is Meyka AI’s outlook for 2228.HK stock
Meyka AI’s forecast model projects monthly HK$16.04 (+29.06%) and 12‑month HK$10.46 (-15.85%) versus the current HK$12.43. These are model-based projections, not guarantees.
Is 2228.HK stock a buy after recent gains
Meyka AI gives 2228.HK a C+ score (58.92/100) with a HOLD suggestion. Consider earnings, partnership milestones and high PS before adding positions; set tight risk controls.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
